Evolus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 02, 2021
November 02, 2021 at 08:08 am EDT
Share
Evolus, Inc. reported earnings results for the third quarter and nine months ended November 02, 2021. For the third quarter, the company reported revenue was USD 26.68 million compared to USD 17.66 million a year ago. Net loss was USD 19.43 million compared to USD 11.46 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.34 a year ago. Diluted loss per share from continuing operations was USD 0.35 compared to USD 0.34 a year ago.
For the nine months, revenue was USD 65.02 million compared to USD 35.96 million a year ago. Net loss was USD 28.63 million compared to USD 52.32 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 1.55 a year ago. Diluted loss per share from continuing operations was USD 0.6 compared to USD 1.55 a year ago.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
EVOLUS, INC. 
